These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 3921437)

  • 1. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent.
    Seltzer V; Vogl S; Kaplan B
    Gynecol Oncol; 1985 Jun; 21(2):167-76. PubMed ID: 3921437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma.
    Richman CM; Podczaski E; Weiser PA; Herbst AL
    Oncology; 1986; 43(1):12-7. PubMed ID: 3079898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
    Posada JG; Marantz AB; Yeung KY; Smith FP; Delgado G; Edwards BK; Schein PS
    Gynecol Oncol; 1985 Jan; 20(1):23-31. PubMed ID: 3917421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
    Carlson JA; Day TG; Botts B; Masterson BJ
    Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients.
    Brower MS; Coleman M; Pasmantier MW; Silver RT; Mamaril AP; Quiguyan CC
    Med Pediatr Oncol; 1984; 12(1):17-24. PubMed ID: 6321930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cis-diamminedichloroplatinum (II): second line induction chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Barlow JJ; Lele SB; Malfetano JH; McPhee ME
    J Surg Oncol; 1983 Dec; 24(4):329-31. PubMed ID: 6418977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Levin L; Simon R; Hryniuk W
    J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinoma.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Kooyman CD; van Houwelingen JC; Pinedo HM
    Cancer; 1984 Apr; 53(7):1467-72. PubMed ID: 6421472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP).
    Bruckner HW; Cohen CJ; Deppe G; Kabakow B; Wallach R; Ratner L; Holland JF
    Gynecol Oncol; 1981 Oct; 12(2 Pt 1):150-3. PubMed ID: 6795095
    [No Abstract]   [Full Text] [Related]  

  • 15. HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.
    Coleman M; Pasmantier MW; Silver RT
    Cancer; 1985 May; 55(10):2342-7. PubMed ID: 3921228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy in recurrent epithelial ovarian cancer (EOC): an analysis of prognostic factors.
    Shamsunder S; Kumar L; Gupta S; Kumar S; Bhatla N; Singh R; Kochupillai V
    J Obstet Gynaecol Res; 2000 Jun; 26(3):215-22. PubMed ID: 10932985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
    Sessa C; Colombo N; Bolis G; Marsoni S; Mangioni C
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():37-46. PubMed ID: 1904308
    [No Abstract]   [Full Text] [Related]  

  • 18. CHAP II therapy for epithelial ovarian cancers following primary treatment with platinum-based combination chemotherapy.
    Schwartz PE; Keating G; Kohorn EI; Chambers JT
    Gynecol Oncol; 1986 Nov; 25(3):340-6. PubMed ID: 3096820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Second-effort" surgical resection for bulky ovarian cancer.
    Vogl SE; Seltzer V; Calanog A; Moukhtar M; Camacho F; Kaplan BH; Greenwald E
    Cancer; 1984 Nov; 54(10):2220-5. PubMed ID: 6435854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.